Certains adénovirus humains (HAdV) comme le sérotype 3 (appartenant au sous-groupe B) sont capables de former des particules pseudo-virales composées des deux protéines impliquées dans l’entrée virale : la base du penton et la fibre (= penton). En effet, 12 pentons sont capables de s’auto-assembler de manière symétrique pour former des particules appelées dodécaèdres (Dd). Dans le présent travail, nous avons modifié et caractérisé les dodécaèdres bases (c’est à dire des Dds sans fibres) de l’HAdV3 afin d’en faire une plateforme vectorielle multi-épitopique versatile appelée ADDomer (ADenovirus Dodecamer). Pour cela, nous avons identifié des régions de la base du penton permettant l’insertion de peptides d’intérêt et créé une plateforme génétique générique permettant l’insertion facile de ceux-ci par biologie synthétique. L’insertion de séquences codant un peptide d’intérêt directement dans le gène de l’ADDomer, résulte dans son exposition de manière multivalente à la surface de la VLP du fait de la pentamérisation puis de la dodécamérisation de la base. L’ADDomer a été produit et caractérisé afin d’évaluer sa capacité à vectoriser des épitopes linéaires ou structuralement complexes. Nous avons ensuite conçu une deuxième stratégie de vectorisation, toujours basée sur l’ADDomer mais cette fois-ci en utilisant l’interaction base/fibre. Un peptide mimant la partie de la fibre de l’HAdV3 (les 20 résidus N-terminaux) interagissant avec la base du penton a été élaboré pour servir d’adaptateur formant des liaisons covalentes avec l’ADDomer.Le comportement de l’ADDomer in vivo a été étudié dans un contexte vaccinal. Pour cela, nous avons injecté l’ADDomer chez la souris afin de valider son transport vers le système lymphatique. Nous avons également démontré que l’ADDomer était capable de s’internaliser dans les monocytes et dans des cellules dendritiques dérivées de monocytes et d’induire les caractères spécifiques de maturation de ces dernières. Fort de ces résultats, nous avons généré un ADDomer vectorisant un épitope du virus Chikungunya décrit pour être la cible d’anticorps neutralisants de patients infectés par ce virus. Pour finir cette étude in vivo, nous avons évalué la capacité de l’ADDomer-TevChik à induire la réponse anti-épitopique et nous avons ainsi démontré que la façon dont l’épitope est présenté à la surface de l’ADDomer était importante pour obtenir une réponse significative. / Some human adenoviruses (HAdV) such as adenovirus derived from serotype 3 (belonging to subgroup B) are able to form virus-like particles composed of the two proteins involved in viral entry: the penton base and the fiber (= penton). Indeed, 12 pentons are able to self-assemble in a symmetrical manner to form penton dodecahedron (PtDd). In the present work, we modified and characterized the base dodecahedron (BsDd = PtDd without fiber) of HAdV3 in order to create a versatile multi-epitopic platform named ADDomer (ADenovirus Dodecamer). We have created a genetic platform allowing easy insertion of epitope(s) of interest (s) thanks to synthetic biology. The insertion of sequences encoding a peptide of interest in the ADDomer gene enable a multivalent exposure at the surface of the VLP due to the pentamerization then to the dodecamerization of the penton base. ADDomer has been produced and characterized to assess its ability to vectorize linear or structurally complex epitopes. We then designed a second vectorization strategy, still based on the ADDomer, but using the interaction penton base / fibre. A peptide mimicking the part of the Ad3 fiber interacting with the penton base (the 20 N-terminal residues) has been designed to serve as an adaptor forming covalent bonds with the ADDomer.The behavior of the ADDomer in vivo has been studied in a vaccine context. For this, we injected the ADDomer in mice to validate its transport to the lymphatic system. We have also demonstrated that ADDomer is able to internalize monocytes and dendritic cells derived from monocytes (MoDC) and induces the specific characters of MoDC maturation. Based on these results, we generated an ADDomer vectorizing an epitope of the Chikungunya virus (ADDomer TevChik) described to be the target of neutralizing antibodies of patients who have been infected by this virus. To conclude this in vivo study, we assessed the ability of ADDomer TevChik to induce the anti-epitopic response and thus demonstrated that the way the epitope is displayed on the surface of the ADDomer was important to obtain a meaningful response.

abstract: Influenza is a deadly disease that poses a major threat to global health. The surface proteins of influenza A, the type most often associated with epidemics and pandemics, mutate at a very high frequency from season to season, reducing the efficacy of seasonal influenza vaccines. However, certain regions of these proteins are conserved between strains of influenza A, making them attractive targets for the development of a ‘universal’ influenza vaccine. One of these highly conserved regions is the ectodomain of the influenza matrix 2 protein (M2e). Studies have shown that M2e is poorly immunogenic on its own, but when properly adjuvanted it can be used to induce protective immune responses against many strains of influenza A. In this thesis, M2e was fused to a pair experimental ‘vaccine platforms’: an antibody fusion protein designed to assemble into a recombinant immune complex (RIC) and the hepatitis B core antigen (HBc) that can assemble into virus-like particles (VLP). The two antigens were produced in Nicotiana benthamiana plants through the use of geminiviral vectors and were subsequently evaluated in mouse trials. Mice were administered three doses of either the VLP alone or a 1:1 combination of the VLP and the RIC, and recipients of both the VLP and RIC exhibited endpoint anti-M2e antibody titers that were 2 to 3 times higher than mice that received the VLP alone. While IgG2a:IgG1 ratios, which can suggest the type of immune response (TH1 vs TH2) an antigen will elicit, were higher in mice vaccinated solely with the VLP, the higher overall titers are encouraging and demonstrate a degree of interaction between the RIC and VLP vaccines. Further research is necessary to determine the optimal balance of VLP and RIC to maximize IgG2a:IGg1 ratios as well as whether such interaction would be observed through the use of a variety of diverse antigens, though the results of other studies conducted in this lab suggests that this is indeed the case. The results of this study demonstrate not only the successful development of a promising new universal influenza A vaccine, but also that co-delivering different types of recombinant vaccines could reduce the total number of vaccine doses needed to achieve a protective immune response. / Dissertation/Thesis / Masters Thesis Molecular and Cellular Biology 2019

Plant viruses have been instrumental in our understanding of the biophysical properties pertaining to non-enveloped icosahedral virus particles. A substantial amount of research has been performed over five decades on Turnip yellow mosaic virus (TYMV), arguably one of the most extensively studied icosahedral plant viruses and the type-member of the Tymovirus plant virus genus. Even with a substantial body of published scientific literature, little is known about the role of specific coat protein (CP) residues in TYMV assembly, disassembly and disencapsidation. We have shown through our mutagenesis studies that the N-terminal region of the CP that is involved in the formation of an annulus structure and is disordered in A-subunit pentamers is not essential in vivo, but annulus-forming residues are critical in ensuring virion stability and low accessibility after virus is purified (Chapter 2). We have shown that a range of amino acid residue types is tolerated within the CP N-terminus in vivo, although they can greatly affect the stability of virions and empty particles, most notably at low pH (Chapter 3). Unlike full-length CP, N-terminal deletion and substitution mutants fail to reassemble into particles in vitro (Chapter 2, 3) suggesting a critical determinant for the N-terminus in reassembly (discussed Chapter 7). This is the first documented in vitro reassembly reported for a member of the Tymoviridae family and should provide a framework for further studies. We have identified a new way to create empty artificial top component (ATC)-particles through treatment with EDTA (Chapter 6) and we also show that tymoviruses can be engineered with altered pH-dependent enhanced stability (Chapter 4). In collaboration with the Qian Wang laboratory from the University of South Carolina we have shown that an RGD (Arg-Gly-Asp) motif can be genetically engineered within the CP of TYMV, resulting in infectious particles with attractive stem-cell adhesion properties (Chapter 5). With focus on basic viral mechanisms, we have crystallized the TYMV virion and ATC particle at pH 7.7 and collected data to less than 5 Å resolution (Chapter 4, supplementary). These structures represent the first tymovirus-based structures solved above pH 5.5 and will provide insight into the N-terminal conformations within the TYMV particle. Finally, we have characterized an N-terminal CP cleavage seen after ATC formation (Chapter 4) suggesting an additional and yet uncharacterized feature associated with decapsidation. / Graduation date: 2012

A virus-like particle (VLP) is a biological nanoparticle. It consists of the protective protein shell of a virus that is devoid of the nucleic acid required for viral replication. VLPs have two key uses: they can act as vaccines by inducing an immune response similar to their native virions, or they can facilitate gene therapy and drug delivery by encapsulating non-viral molecules and efficiently transporting them into cells. Manufacture of VLPs involves cell-based expression of virus-shell protein, with particle assembly and purification following one of two paradigms: (i) in vivo VLP assembly, followed by purification of full particles from cell lysate; (ii) partially assembled protein is recovered from cell lysate and assembled into VLPs in vitro. The flexibility and efficiency of both of these VLP manufacturing paradigms can be improved by first gaining a fundamental understanding of what is happening at key process steps. These improvements will lower the cost of VLP manufacture and enhance the viability of VLP products in the biopharmaceutical marketplace. The research reported here yielded positive outcomes for two key steps of the VLP manufacturing process, using murine polyomavirus VLPs for all experimentation. Firstly, enhanced understanding concerning the capture of virus shell protein in pentamer form (capsomeres) from cell lysate using glutathione-S-transferase (GST) affinity chromatography was obtained. It was discovered that prokaryotic expression of GST-tagged capsomeres yielded soluble aggregates having variable size distribution. Methods were developed to physically and chemically characterise these soluble aggregates, and the mechanism by which they adsorb to the chromatography resin was described using an established mathematical model. Secondly, particle characterisation of whole VLPs isolated from cell lysate was undertaken. Methods utilizing three orthogonal and quantitative techniques were developed to suggest that encapsulation of non-viral molecules (nucleic acids or proteins) during in vivo assembly causes distinct changes to the size distribution of isolated VLPs: transmission electron microscopy (TEM), asymmetrical flow field-flow fractionation with multiple-angle light scattering (AFFFF-MALS) and electrospray differential mobility analysis (ES-DMA). The understanding gained from the research presented in this work enables the enhanced capture of partially assembled virus shell protein from cell lysate, as well as a method to efficiently and cost-effectively analyse VLP solutions for the presence of desirable or undesirable encapsulated material.

A virus-like particle (VLP) is a biological nanoparticle. It consists of the protective protein shell of a virus that is devoid of the nucleic acid required for viral replication. VLPs have two key uses: they can act as vaccines by inducing an immune response similar to their native virions, or they can facilitate gene therapy and drug delivery by encapsulating non-viral molecules and efficiently transporting them into cells. Manufacture of VLPs involves cell-based expression of virus-shell protein, with particle assembly and purification following one of two paradigms: (i) in vivo VLP assembly, followed by purification of full particles from cell lysate; (ii) partially assembled protein is recovered from cell lysate and assembled into VLPs in vitro. The flexibility and efficiency of both of these VLP manufacturing paradigms can be improved by first gaining a fundamental understanding of what is happening at key process steps. These improvements will lower the cost of VLP manufacture and enhance the viability of VLP products in the biopharmaceutical marketplace. The research reported here yielded positive outcomes for two key steps of the VLP manufacturing process, using murine polyomavirus VLPs for all experimentation. Firstly, enhanced understanding concerning the capture of virus shell protein in pentamer form (capsomeres) from cell lysate using glutathione-S-transferase (GST) affinity chromatography was obtained. It was discovered that prokaryotic expression of GST-tagged capsomeres yielded soluble aggregates having variable size distribution. Methods were developed to physically and chemically characterise these soluble aggregates, and the mechanism by which they adsorb to the chromatography resin was described using an established mathematical model. Secondly, particle characterisation of whole VLPs isolated from cell lysate was undertaken. Methods utilizing three orthogonal and quantitative techniques were developed to suggest that encapsulation of non-viral molecules (nucleic acids or proteins) during in vivo assembly causes distinct changes to the size distribution of isolated VLPs: transmission electron microscopy (TEM), asymmetrical flow field-flow fractionation with multiple-angle light scattering (AFFFF-MALS) and electrospray differential mobility analysis (ES-DMA). The understanding gained from the research presented in this work enables the enhanced capture of partially assembled virus shell protein from cell lysate, as well as a method to efficiently and cost-effectively analyse VLP solutions for the presence of desirable or undesirable encapsulated material.

No description available.

Porcine reproductive and respiratory syndrome virus (PRRSV) and porcine epidemic diarrhea virus (PEDV) are two of the most prevalent swine pathogens that have impacted the global swine industry for decades. Both are RNA viruses with increasing heterogeneity over the years, making a vaccine solution ever so challenging. Modified live-attenuated vaccines (MLVs) have been the most common approach, but the long-term safety regarding their potential for pathogenic reversion still needs to be addressed. Subunit based vaccines have been the focus of numerous development studies around the world with renewed interest in their promising prospects in both safety and efficacy. Our lab has developed a unique approach to use hepatitis B virus core capsid protein (HBcAg) as a vaccine delivery vehicle for either PRRSV or PEDV viral epitope antigens. Recombinantly produced HBcAg forms an icosahedral capsid virus-like particle (VLP) that has 240 repeats in a single assembled particle. By inserting different epitope antigens from these porcine pathogens into the particle, we can achieve repetitive antigen presentation to the host's immune system by taking advantage of the polymeric nature of VLP. The first animal study evaluated the efficacy of 4 VLP based vaccine candidates against PRRSV in mice. These 4 vaccines incorporated 2 B-cell epitopes (61QAAIEVYEPGRS72 and 89ELGFVVPPGLSS100) and 2 T-cell epitopes (117LAALICFVIRLAKNC131 and 149KGRLYRWRSPVIIEK163) from PRRSV structural proteins GP3 and GP5 respectively. Candidate GP3-4 was able to stimulate a significant viral neutralizing response in mouse sera against two PRRSV strains, one being heterologous, demonstrating its potential of cross-protection against PRRSV. The second animal study took an optimized VLP vaccine candidate against PEDV from previous development studies in mice, and assessed its efficacy through a comprehensive pregnant gilt vaccination and neonatal piglet challenge model. The vaccine candidate incorporated B-cell epitope 748YSNIGVCK755 from the PEDV spike protein. It was able to elicit significant viral neutralization antibody titer in gilt milk at 3 days post-farrowing (DPF), and provided nursing piglets with clinical relief in terms of morbidity, viral shedding, small intestinal lesions, and 10 days post-challenge (DPC) survival rate. / Doctor of Philosophy / Porcine reproductive and respiratory syndrome virus (PRRSV) and porcine epidemic diarrhea virus (PEDV) are two pathogens that infect pigs, resulting in immense economic losses to the global pork production industry every year. Both viruses have large diversity with various strains due to mutations that have occurred over the years. This makes vaccine development that aims at combating the pathogens even more challenging. One common vaccine strategy has been immunizing animals with modified live viruses with decreased pathogenicity. Naturally, long term safety of this option has been a concern. A much safer vaccine approach that is purely protein based has attracted renewed interest around the world. Protein based vaccines lack genetic materials from the viruses and are not able to replicate inside the host. Our lab has developed a platform that uses protein-based particles (VLPs) originated from the hepatitis B virus (HBV), and incorporates short pieces of proteins from either PRRSV or PEDV to train host's immune system to recognize these pathogens, and hopefully to prevent future infection. For the first animal study, we tested 4 VLP vaccine candidates against PRRSV in mice and discovered that mouse serum from one candidate GP3-4 was able to prevent infection of 2 distinct PRRSV strains in petri dishes, paving the way for further development. For the second animal study, we took an optimized VLP vaccine candidate against PEDV from previous mouse studies, and evaluated its performance in pigs. We immunized pregnant mother pigs with the vaccine before they gave birth, then experimentally infected newborn piglets with the virus. Piglets from the vaccinated mothers showed improved clinical signs and faster recovery from the infection.

<p dir="ltr">The Ebola virus (EBOV) is a filamentous RNA virus which causes severe hemorrhagic fever. It is one of the most dangerous known pathogens with a high fatality rate. Multiple outbreaks of EBOV have occurred since the 1970s with the most widespread outbreak starting in December 2013. This outbreak continued through May of 2016 and had a fatality rate of approximately 50%. EBOV outbreaks are recurrent because the virus is still present in animal reservoirs. Despite multiple EBOV outbreaks we still lack a clear understanding of how new viral particles are formed and spread through virus assembly and release. Given the widespread global travel, EBOV now poses a threat to the entire world. EBOV encodes for the matrix protein, VP40, which is one of the most conserved viral proteins. VP40 can form different structures leading to different functions of the protein in different stages of the EBOV life cycle. The VP40 dimer traffics to the inner leaflet of the plasma membrane to facilitate assembly and budding. The VP40 octameric ring has been implicated in transcriptional regulation. This thesis focuses on understanding in further detail the determinates of VP40 plasma membrane assembly and exit from an infected cell.</p><p dir="ltr">The assembly and trafficking of VP40 to the plasma membrane requires a network of protein-protein and lipid-protein interactions (PPIs and LPIs). Studying these interfaces is important for understanding how VP40 structure and function regulates trafficking and assembly and can shed light on therapeutic strategies to target EBOV. The alteration of host cell Ca²⁺ levels is one of the strategies that viruses use to perturb the host cell signaling transduction mechanism in their favor. Evidence has emerged demonstrating that Ca²⁺ is important for the assembly and budding of EBOV in a VP40-dependent manner. The relationship between intracellular Ca²⁺ levels and EBOV matrix protein VP40 function is still unknown. In this work we utilize biophysical techniques to study the role of LPIs and intracellular Ca²⁺ on VP40 dynamics at the plasma membrane and key residues for assembly and budding. This work highlights the sensitivity of slight electrostatic changes on the VP40 surface for assembly and budding and a critical interaction between Ca²⁺ and the VP40 dimer that are important for lipid binding at the plasma membrane.</p>

No description available.

Das in Europa vorkommende Dobravavirus (DOBV) gehört zu den Hantaviren und wird durch die Gelbhalsmaus Apodemus flavicollis übertragen und kann im Menschen zu einem "Hämorrhagischen Fieber mit renalem Syndrom" (HFRS) führen. Das Nukleokapsidprotein (N) von Hantaviren ist stark immunogen in Menschen und eine Impfung mit rekombinanten N Derivativen wie chimaere Hepatitis B Virus (HBV) Corepartikel oder das komplette N schützt in Nagetiermodellen vor einer Hantavirusinfektion. In der vorliegenden Arbeit wurde die Immunogenität von zwei auf dem DOBV N basierende Protein Derivativen in Mäusen getestet. Es wurden in E. coli exprimierte chimaere HBV Corepartikel verwendet, die einen Teil des DOBV N trugen (HBcdDOB120), sowie in Hefen eprimiertes komplettes DOBV rN. Anschließend wurden BALB/c und C57BL/6 Mäuse mit den jeweiligen Proteinen immunisiert. Sowohl BALB/c, als auch C57BL/6 Mäuse entwickelten eine starke, langanhaltende N-spezifische Antikörperantwort, die eine starke Kreuzreaktivität gegenüber der rN anderer Hantaviren aufwiesen, nach Impfung mit HBcdDOB120 oder DOBV rN-Protein. Es wurden Antikörper aller IgG Subklassen, sowie N-spezifische IFN-( und IL-4 sekretierende Lymphozyten induziert, was auf eine gemischte Th1/Th2 Antwort schließen lies. Die Frequenz der durch die Immunisierungen induzierte N-spezifischen Lymphozyten war allerdings gering. Auch in Mäusen, die hohe HBc-spezifische Antikörpertiter aufwiesen konnte eine starke N-spezifische Antikörperantwort mittels Impfung mit HBcdDOB120 induziert werden. HBcdDOB120 und DOBV rN stellen vielversprechende Vakzinekandidaten dar, die auf ihre Protektivität hin getestet werden sollten. Da HBcdDOB120 sowie DOBV rN eine starke Antikörperantwort und nur eine schwache T-Zellantwort induzieren sollte zusätzlich die Rolle von N-spezifischen Antikörpern im Schutz gegen die Virusinfektion weiter charakterisiert werden. / In Europe, the hantavirus Dobrava (DOBV) is carried by the yellow-necked mouse Apodemus flavicollis and causes "haemorrhagic fever with renal syndrome" in humans. The nucleocapsid protein (N) is very immunogenic in infections of humans and rodents. Immunisation with N protein derivatives, like chimeric hepatitis B virus core (HBc) particles and entire recombinant N could protect rodents from a hantavirus infection. In this study, the immunogenicity of the two following derivatives based on the DOBV N protein was tested in mice. Chimeric HBV core particles, consisting of truncated HBc (HBcd) particles carrying part of the DOBV N (HBcdDOB120) were expressed in E. coli and the entire DOBV rN in yeast. Hence BALB/c and C57BL/6 mice were immunised subcoutanously with both antigens. Mice of both strains elicited strong and longlived N-specific antibody responses after HBcdDOB120 as well as after DOBV rN immunisation. Both derivatives induced antibodies that were highly cross-reactive to the rN of the hantaviruses Puumala, Hantaan, Andes and Sin Nombre. HBcdDOB120 and DOBV rN induced N-specific antibodies of all IgG subclasses, suggesting a mixed Th1/Th2 immune response. In the same line, IFN-( and IL-4 was secreted by N-specific lymphocytes from mice immunised with HBcdDOB120 or DOBV rN after in vitro restimulation which also indicated a mixed Th1/Th2 response. However, the frequency of N-specific lymphocytes was low. In mice that exhibited a high HBc-specific antibody titer HBcdDOB120 also induced a strong N-specific immune response. HBcdDOB120 and DOBV rN represent promising vaccine candidates that should be tested for their protective potential in a DOBV challenge model as soon as one gets available. Additionally, as protection might be partially based on N-specific antibodies, their role in protecting against a hantavirus infection should be characterised further.